The Prospective Oral Mucositis Audit was an observational study in 197 patients with multiple myeloma (MM) or non-Hodgkin's lymphoma (NHL) undergoing, respectively, high-dose melphalan or BEAM chemotherapy and autologous SCT at 25 European centres. We evaluated the relationship between severe oral mucositis (SOM; WHO Oral Toxicity Scale grade 3-4) and local and systemic clinical sequelae and medical resource use. SOM occurred in 44% of patients. The duration of SOM (mean 5.3 days) correlated with time to neutrophil engraftment. The following parameters increased gradiently with maximum grade of oral mucositis: duration of pain score X4, opioid use, dysphagia score X4, total parenteral nutrition (TPN) use, incidence and/or duration of fever and infection, and duration of antibiotic use. SOM increased the duration of TPN use by 2.7 days (Po0.001), opioids by 4.6 days (Po0.001), and antibiotics by 2.4 days (P ¼ 0.045). SOM prolonged hospital stay by 2.3 days (P ¼ 0.013) in MM patients, but not in NHL patients (who tended to have a longer hospital stay).
Introduction
Oral mucositis (OM) is a very common debilitating adverse event in patients receiving high-dose chemotherapy and SCT, 1 and results from damage to both epithelial and submucosal tissues by the conditioning regimen. 2 Clinical manifestations of OM include signs and symptoms of an inflammatory process, ranging from mild erythema, oedema and soreness to extreme pain and ulceration. Severe OM interferes with daily activities such as speaking, eating and swallowing and has a negative impact on quality of life. 3, 4 It can lead to dehydration, malnutrition and serious infections [5] [6] [7] [8] and has been linked to inferior overall survival (P ¼ 0.002) after SCT. 6 Several US-based analyses from various cancer settings have demonstrated that severe OM increases healthcare resource utilization by necessitating opioid analgesia, antiinfective treatment, total parenteral nutrition (TPN) and subsequently prolonging hospitalization. 3, 5, 8, 9 However, medical resource use in relation to OM has not been systematically assessed in the European SCT setting, although a recently published overview provided insights in the management of OM in European transplantation centres. 10 The Prospective Oral Mucositis Audit (POMA), conducted by our group in 25 centres across 13 European countries, was the first multi-country audit study with OM occurrence as the primary objective. The first part of the analysis (described in our initial paper) revealed a high incidence of severe (World Health Organization (WHO) oral toxicity scale grade [3] [4] 11 OM (44%) in patients with multiple myeloma (MM) or non-Hodgkin's lymphoma (NHL) who underwent high-dose dose melphalan or BEAM conditioning, respectively and autologous SCT. 1 Severe OM risk and/or duration were significantly associated with higher chemotherapy dose per kg body weight and poor performance status, but in contrast to some previous reports they were not related to age.
The POMA study also aimed to evaluate the clinical sequelae of OM, including pain, dysphagia, fever and infection, and to examine its impact on the use of healthcare resources, including TPN, opioids and antibiotics, and duration of hospitalization. We present here the results of these analyses.
Patients and methods

Study design and patient population
The POMA design has been described previously. 1 ; NHL patients) conditioning chemotherapy followed by autologous SCT. Exclusion criteria were previous SCT/BMT, palifermin administration and presence of oral abnormalities at baseline. Prophylaxis and treatment for OM and its clinical sequelae were according to local clinical practice. Ethical approval was obtained according to country-specific requirements and all patients provided written informed consent.
Patients were selected from European transplant units, which had a history of reporting patients to the European Society for Bone and Marrow Transplantation registry. Centres were selected in which patients received autografts as inpatients to monitor 'mucositis' accurately. Centres were selected to represent a wide spectrum of European countries and to allow training of nurses to be a practical proposition.
Study assessments and data collection Data collection included baseline demographic and medical characteristics and type and dosage of conditioning chemotherapy. OM assessments were conducted daily from day 1 of conditioning chemotherapy until 30 days post transplantation or hospital discharge (whichever occurred first), using the five-point WHO oral toxicity scale (grade 1: soreness and erythema, no further symptoms; grade 2: ulcers present, but solid diet possible; grade 3: only liquids can be swallowed; grade 4: oral alimentation impossible). To achieve consistent high-quality OM assessment, on-site nurse assessors and physicians underwent an intensive training programme. 12 Ulcerative OM was defined as WHO scale score 2-4 and severe OM as WHO scale score 3-4. Specific 10-point scales were used to record local signs and symptoms of severe OM (0 ¼ no symptoms present; 10 ¼ worst possible symptoms, as judged by patients). Body temperature was recorded on the daily OM assessment forms. Time to neutrophil engraftment (40.5 Â 10 9 /l) was retrieved from the European Society for Bone and Marrow Transplantation Promise database. Information on infections and use of medical resources, including medications used for OM prophylaxis and treatment was obtained from the study sites. Medication categories included mouthwashes, opioid analgesics, antibiotics, antifungals, antivirals and other medications. These categories were not prospectively defined and were therefore open to interpretation by site staff. However, drug names were requested for verification purposes (except in the case of mouthwashes, as local preparations were often used). No on-site monitoring was performed for this study.
Statistical methodology
Clinical end points included in this analysis were: WHO oral toxicity scale score; duration of pain score X4, and dysphagia score X4; incidence and duration of fever (X38.0 1C), incidence of infection (clinically defined or microbiologically confirmed) and of microbiologically confirmed bacterial infection before day 30 post transplantation, and time to neutrophil engraftment. Medical resource utilization end points were duration of TPN, opioid analgesic and antibiotic use and duration of hospitalization.
The WHO scoring system was chosen because most European transplant centres were familiar with this instrument based on a survey by the nurses' group of the European Society for Bone and Marrow Transplantation. 10 Missing WHO scale and pain score values during the audit period were interpolated and missing values at the beginning or end of the audit period extrapolated. For the purpose of longitudinal assessments, a grade of 0 was also imputed after patient discharge and fever and dysphagia were assumed to be absent after patient discharge. Temporal patterns were assessed by plotting mean daily WHO scale-based OM scores and applicable symptom-specific scores over the audit period. The proportion of patients with fever was plotted in a similar way.
Using univariate analyses, associations of interest were assessed using the w 2 test, the non-parametric Mann-Whitney U-test or the Spearman's correlation coefficient and its P-value, as appropriate. Multivariate Poisson regression was used to further assess the impact of severe OM on the duration of hospitalization. Parameters that were explored as potential determinants of length of hospital stay included baseline characteristics (age, sex, weight, height, body surface area, Eastern Cooperative Oncology Group (ECOG) performance status, type and dosage of chemotherapy), time to neutrophil engraftment, as well as infection-related parameters (incidence and duration of fever and incidence of infection and microbiologically confirmed bacterial infection before day 30 post transplantation-which would be difficult to interpret in models of OM occurrence).
Random effects modelling was used to assess possible distortions of the main study results by centre effects.
Poisson regression used generalized estimation equations (GEE)-based robust s.e. estimates to allow for clustering by study centre. Statistical analyses were performed using the STATA/SE version 9 statistical software package. Statistical tests were two-sided at the 5% significance level. Twosided 95% confidence intervals are shown.
Results
Study population
Patient baseline characteristics and conditioning chemotherapy doses for the 197 evaluable patients enrolled into POMA (109 patients (55. 3%) with MM and 88 (44.7%) with NHL) are summarized in Table 1 . Mean recruitment per centre ± s.d. was 7.9 ± 4.8 patients (range, 1-18). In the MM group, the mean age was higher and there were fewer women, consistent with the epidemiology of this disease. The audit period lasted (mean ± s.d.) 19.8 ± 4.5 days in the MM group and 22.4 ± 3.7 days in the NHL group. The time from first chemotherapy administration to transplantation was longer in the NHL group than in the MM group (median 7 vs 3 days), as BEAM is typically administered over 5 days and high-dose melphalan over 1-2 days. Patients received various types of OM prophylaxis, including mouthwashes (78% of patients), antibiotics (36%), antifungals (54%) and antivirals (44%), according to local practice. The most frequently used antifungal substance was fluconazole, followed by itraconazole, systemic or local amphotericin B, and nystatin. Antivirals were aciclovir or valaciclovir.
Evolution of OM
A total of 87 (44.2%). of 197 patients experienced severe OM (46% in patients with MM and 42% in patients with NHL), with a mean duration of 5.3±3.2 days: there were no relevant differences between MM and NHL patients with regard to these end points. A significant amount of variation between centres with respect to these end points was noted but random effects modelling yielded no indication of a related distortion of the overall results. The temporal relationship of WHO scale score with pain and dysphagia scores, fever and neutrophil engraftment is shown in Figure 1 . The median onset of ulcerative OM and of severe OM was on days 11 and 12, respectively, after the start of conditioning chemotherapy. This coincided with median onset of fever, infection and microbiologically confirmed bacterial infection, both in patients with and in patients without severe OM. The peak level of discomfort was experienced on days 12-13 and this coincided with the beginning of neutrophil engraftment (Figure 1) . The relationship of maximum grade of OM and clinical and healthcare resource outcomes is summarized in Table 2 .
Pain and opioid use Not surprisingly, the duration of pain score X4 increased gradiently with the maximum WHO OM scale score (Po0.001), reaching a mean duration of 6.5 days in patients with WHO grade 4 OM. Opioid analgesic use also increased across the OM grades (Po0.001), patients with Fever and antibiotic use Fever, infection and microbiologically confirmed infection, increased with increasing grade of OM (Table 2 ). Comparison of patients with and without severe OM showed that patients with severe OM had a higher incidence of fever (68 vs 47% of patients; difference 21%; P ¼ 0.004), infection (42 vs 24%; P ¼ 0.013) and microbiologically confirmed bacterial infection (27 vs 12%; P ¼ 0.013), and a longer duration of fever (4.2 vs 3.0 days; P ¼ 0.033). The duration of severe OM (in patients who developed severe OM) mostly showed the same associations, but it was not significantly associated with the incidence of infection or of microbiologically confirmed bacterial infection (data not shown). Combined duration of antibiotic use with prophylactic and therapeutic intent also increased across OM grades (Table 2) , patients with severe OM receiving an additional 2.4 days of antibiotics (P ¼ 0.045) compared with those without severe OM.
Neutrophil engraftment
Time to neutrophil engraftment did not show any clear correlation with the maximum grade of OM (Table 2) or severe OM incidence, but it was positively correlated with the duration of severe OM (Spearman's correlation coefficient 0.27; P ¼ 0.012). This observation was confirmed when time to neutrophil engraftment was tentatively allowed as an additional covariate in the multivariate analysis of severe OM duration (Po0.001), as noted in our earlier analysis. 1 
Length of hospital stay
Length of hospital stay increased with increasing severity of OM in patients with MM, ranging from 17.0±5.4 days in patients with no OM to 21.5 ± 3.7 days in patients with grade 4 OM, with severe OM prolonging hospital stay by 2.3 days (P ¼ 0.013). However this trend was less clear in patients with NHL, who tended to have a longer hospital stay than patients with MM (Table 2) .
Multivariate Poisson regression analysis showed that higher age, higher baseline Eastern Cooperative Oncology Group performance status, longer duration of severe OM, longer time from start of conditioning to transplantation and longer time from transplantation to neutrophil engraftment were associated with significantly longer hospitalization ( Table 3 ). The impact of duration of severe OM on duration of hospitalization was attenuated by both time to transplantation and time to neutrophil engraftment ( Table 3 ) (indicating that the effect of duration of severe OM on hospital stay is reduced if hospitalization is prolonged anyway). When indicators of fever or infection were added to the model, the effect of severe OM duration was also attenuated. A similar pattern was seen using incidence, instead of duration, of severe OM in the analysis.
Discussion
The initial analysis of the POMA findings provided the first prospective, robust data on patterns and determinants of severe OM in patients undergoing high-dose melphalan or BEAM chemotherapy and autologous SCT. 1 This second analysis of data from this pan-European audit provides new insights into the clinical sequelae of severe OM and associated medical resource use.
Consistent with other observations, 8, 13 we found that severe OM was closely related to development of fever, with the incidence of fever being 21% higher and the duration of fever 1.2 days longer, in those with severe OM. Previous studies in the SCT setting have shown that the risk of fever and/or febrile neutropenia (FN) increases with increasing grade of OM. 8, 9 Moreover, the recombinant growth factor palifermin, which protects the oral mucosa from damage induced by myelotoxic-conditioning treatment, was able to reduce the risk of FN in patients undergoing SCT. 14 The association of fever with oral mucositis has been attributed to local and systemic infections, as disruption of the mucosal barrier may provide an entry point for pathogens. 2, 13 However, infection frequently cannot be documented in febrile patients. An alternative hypothesis is that fever may be a manifestation of the inflammatory process that is induced by conditioning chemotherapy 2, [15] [16] [17] and driven by acute phase cytokines such as tumour necrosis factor a (TNF-a) and interleukin 6 (IL-6). 17, 18 Mucositis itself is also a potential source of local and systemic cytokines. These cytokines can induce sepsis-like signs and symptoms when administered exogenously to humans. Indeed, one study found that blood levels of TNFa and IL-6 were significantly correlated with changes in body temperature in cancer patients who were administered TNF. 19 We found that severe OM duration was positively correlated with time to neutrophil engraftment and that engraftment coincided with peak OM scores (Figure 1 ). This supports previous observations that healing of OM coincides with neutrophil recovery. [20] [21] [22] [23] Although some investigators have failed to find a link between OM and neutropenia, 5, 24 Rapoport et al. 25 noted that duration of neutropenia was a risk factor for OM and the severity of OM has been linked to the degree of neutropenia. 26 Oral neutrophil kinetic studies (using mouth rinses) in patients recovering from profound neutropenia have demonstrated that neutrophils are present in the tissues before peripheral neutrophil counts recover, 21, 27, 28 consistent with their important role in mucosal defence and repair. A study in the BMT setting found that neutrophil levels in mouth rinses decreased to undetectable levels during the neutropenic period, but recovered 1-2 and 3-9 days before peripheral neutrophil counts reached 0.1 and 1.0 Â 10 9 /l, respectively, regardless of whether or not patients received granulocyte-colony stimulating factor (G-CSF) support. 21 A study in paediatric SCT patients found that the return of neutrophils to the oral cavity marked the beginning of the mucosal recovery phase. Moreover, the time span between oral and peripheral neutrophil recovery was inversely related to the number of infection-related febrile episodes occurring after peripheral engraftment. 27 Duration of severe OM was associated with the duration of hospitalization, and development of severe OM prolonged the hospital stay by 2.3 days (P ¼ 0.013) in MM patients. However, fever and infection were cofactors in prolonging hospitalization. Therefore, if severe OM is itself a causative factor in fever and infection (Table 2) , including these covariates may lead to underestimation of the effect of severe OM on duration of hospitalization, a major driver of costs in this setting. Other factors influencing hospital stay were age, baseline Eastern Cooperative Oncology Figure 1 ). Our findings are consistent with earlier data from the United States. An earlier prospective, multicentre study in blood or marrow transplant recipients (n ¼ 92) 8 and a retrospective chart review in SCT recipients (n ¼ 281) 9 found that resource use and clinical outcomes, including duration of hospitalization, were significantly correlated with the severity of OM. A retrospective case-control study in 24 patients who developed a-haemolytic streptococcal bacteraemia following autologous BMT 13 found that OM prolonged hospital stay both independently and as a cofactor associated with bacteraemia.
Systemic drug exposure was a key determinant of severe OM risk in our previous analysis, 1 in line with other observations. 29, 30 Indeed, a recent study by a German group found that patients treated with a melphalan dose X70 mg/m 2 had a 23-fold increased risk of developing mucositis (Po0.001) compared with those receiving lower doses. 30 Thus, we tentatively evaluated whether there was an association between melphalan dose per kg body weight and medical resource use, in MM patients only. No relationship was found, indicating that the observed associations of OM with medical resource use were not directly on account of higher drug doses.
Changes in guidelines to prevent or treat OM have recently been reviewed 31 and include the use of cryotherapy (ice-water or chips) during the infusion of high-dose melphalan; however, the authors also state: 'However, additional and sustained efforts will be required to gain a fuller understanding of the pathobiology, impact on overall patient status, optimal therapeutic strategies, and improved educational programs for health professionals, patients, and caregivers'.
In conclusion, our analysis of prospectively collected observational data has provided important insights into the scope and impact of severe OM in patients undergoing SCT in routine clinical practice in Europe. The correlation of severe OM with serious systemic sequelae such as infection and increased use of healthcare resources, together with the adverse impact on patient quality of life, underlines the need for effective measures for preventing OM. It is hoped that our findings will help to guide the use of novel preventive treatments.
